



August 19, 2022

The Manager- Listing **BSE Limited**Corporate Relationship Dept., 5<sup>th</sup> Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,

Mumbai - 400001

The Manager- Listing

National Stock Exchange of India Limited

Exchange plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block

Bandra –Kurla Complex, Bandra (E),

Mumbai - 400051

Dear Sir(s),

Sub: AstraZeneca Pharma India Limited receives Import and Market Permission in Form CT-20 (Subsequent New Drug Approval) from the Drugs Controller General of India for Olaparib 100mg/150mg film coated tablets for Additional Indication

This is to inform that AstraZeneca Pharma India Limited has received Import and Market permission in Form CT-20 (Subsequent New Drug Approval) from the Drugs Controller General of India for Olaparib Film-Coated tablets 100 mg and 150 mg - additional indication.

Through this approval, Olaparib Film-Coated tablets 100 mg and 150 mg is additionally indicated as a monotherapy for the adjuvant treatment of adult patients with BRCA-mutated HER2- negative high risk early breast cancer who have previously been treated with neoadjuvant or adjuvant chemotherapy.

The receipt of this permission paves way for the launch of Olaparib Film-Coated Tablets 100 mg and 150 mg (Lynparza®) in India for the specified additional indication, subject to the receipt of related statutory approvals and licenses.

We request you to kindly take the same on record.

For AstraZeneca Pharma India Limited

Manasa. R Company Secretary

TEL: +91 80 6774 9000